Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -66.64% is 991% below its 5-year average of -6.11%, near the low end of its 5-year range (-66.64%–5.58%).
177.84% below its 12-month average of -23.99%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -15.16%.
RETURN ON ASSETS (ROA)
-66.64%
RETURN ON ASSETS (ROA) AVG TTM
-23.99%
RETURN ON ASSETS (ROA) AVG 3Y
-11.65%
RETURN ON ASSETS (ROA) AVG 5Y
-6.11%
RETURN ON ASSETS (ROA) AVG 10Y
-3.64%
RETURN ON ASSETS (ROA) AVG 15Y
-1.31%
RETURN ON ASSETS (ROA) AVG 20Y
-4.75%
CURRENT VS TTM AVG
-177.84%
CURRENT VS 3Y AVG
-472.14%
CURRENT VS 5Y AVG
-991.27%
CURRENT VS 10Y AVG
-1732.14%
CURRENT VS 15Y AVG
-4971.54%
CURRENT VS 20Y AVG
-1303.99%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-106.54%
vs the sector median at left
Vanda Pharmaceuticals Inc.
Market Cap
$271.81M
Return on Assets (ROA)
-66.64%
TTM Avg
-23.99%
3Y Avg
-11.65%
5Y Avg
-6.11%
Market Cap
$270.80M
Return on Assets (ROA)
-4.08%
TTM Avg
-58.27%
3Y Avg
-50.03%
5Y Avg
-43.16%
Market Cap
$266.92M
Return on Assets (ROA)
-48.44%
TTM Avg
-42.51%
3Y Avg
-39.18%
5Y Avg
-34.60%
Market Cap
$266.59M
Return on Assets (ROA)
-5.36%
TTM Avg
-34.75%
3Y Avg
-39.14%
5Y Avg
-23.69%
Market Cap
$265.78M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
Market Cap
$264.25M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$280.37M
Return on Assets (ROA)
-48.34%
TTM Avg
-34.05%
3Y Avg
-4876.46%
5Y Avg
-3907.18%
Market Cap
$262.92M
Return on Assets (ROA)
-45.18%
TTM Avg
-124.83%
3Y Avg
-176.38%
5Y Avg
-195.56%
Market Cap
$281.54M
Return on Assets (ROA)
-26.24%
TTM Avg
-12.09%
3Y Avg
-27.60%
5Y Avg
-33.24%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | $271.81M | -66.64% | -23.99% | -11.65% | -6.11% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | -4.08% | -58.27% | -50.03% | -43.16% |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | -48.44% | -42.51% | -39.18% | -34.60% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | -5.36% | -34.75% | -39.14% | -23.69% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | -134.38% | -47.50% | -42.91% | -40.55% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | -48.34% | -34.05% | -4876.46% | -3907.18% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -45.18% | -124.83% | -176.38% | -195.56% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | -26.24% | -12.09% | -27.60% | -33.24% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | -37.07% | -27.27% | -64.53% | -52.03% |
ROA
-66.6%
ROE
-124.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -45.09% |
| 2024-12-31 | -2.88% |
| 2023-12-31 | 0.39% |
| 2022-12-31 | 0.99% |
| 2021-12-31 | 5.58% |
| 2020-12-31 | 4.37% |
| 2019-12-31 | 23.89% |
| 2018-12-31 | 7.59% |
| 2017-12-31 | -7.58% |
| 2016-12-31 | -8.56% |
| 2015-12-31 | -18.71% |
| 2014-12-31 | 11.76% |
| 2013-12-31 | -14.13% |
| 2012-12-31 | -20.42% |
| 2011-12-31 | -5.37% |
| 2010-12-31 | 3.37% |
| 2009-12-31 | -15.89% |
| 2008-12-31 | -102.26% |
| 2007-12-31 | -76.47% |
| 2006-12-31 | -175.15% |
| 2005-12-31 | -66.80% |
| 2004-12-31 | -53.37% |
